http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Exagen Inc. Secures Conditional NY State Approval for New Lupus and Rheumatoid Arthritis Biomarkers and Announces Select Preliminary 2024 Financial Results
-
Exagen Inc. Reports Third Quarter 2024 Results
-
Exagen Inc. to Participate in the 2024 Cantor Global Healthcare Conference
-
Exagen Inc. Reports Strong Second Quarter 2024 Results: Raises Guidance due to Record Performance
-
Exagen Inc. to Participate in the Canaccord Genuity 44th Annual Growth Conference
-
Exagen Inc (XGN) Appoints Jeffrey G. Black as CFO
-
Exagen Appoints Jeffrey G. Black as New Chief Financial Officer
-
Exagen to Announce Second Quarter 2024 Results on August 5, 2024
-
Exagen Inc. Reports Strong First Quarter 2024 Results: Raises Guidance for Full Year
-
Exagen Announces Campaign for Lupus Awareness Month
-
Exagen to Announce First Quarter 2024 Results on May 13, 2024
-
Exagen Inc (XGN) Announces Board Changes
-
Exagen Inc. Announces Changes to the Board of Directors
-
Exagen Inc. Announces Changes to the Board of Directors
-
Exagen Inc. Reports Strong Fourth Quarter and Full-Year 2023 Results
-
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
-
Exagen Inc. to Participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum
-
Exagen to Announce Fourth Quarter 2023 and Full-Year Financial Results on March 18, 2024
-
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
Exagen Inc. to Participate in the 2024 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
Exagen Inc (XGN) Reports Prelim FY23 Results, Reaffirms Guidance
-
Exagen Inc. Announces Select Preliminary Full-Year 2023 Results and Reaffirms Guidance
-
Exagen Inc. Reports Strong Third Quarter 2023 Results
-
Exagen Inc. and Johns Hopkins University Announce License Agreement for Novel Patented Lupus Nephritis Biomarkers
-
Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
-
Exagen Inc. to Participate in the 2023 Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
-
Exagen to Announce Third Quarter 2023 Financial Results on November 13, 2023
-
Exagen Inc. to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
-
Exagen Inc. Reports Strong Second Quarter 2023 Results
-
Exagen Inc. to Participate in the Canaccord Genuity 43rd Annual Growth Conference
-
Exagen to Announce Second Quarter 2023 Financial Results on August 7, 2023
-
Exagen Inc (XGN) Appoints Paul Kim to its Board
-
Exagen Inc. Appoints Paul Kim to Board of Directors
-
Exagen Inc. to Participate in the William Blair 43rd Annual Growth Stock Conference
-
Exagen Inc. Reports First Quarter 2023 Results
-
Exagen Announces Campaign for Lupus Awareness Month
-
Exagen Announces Campaign for Lupus Awareness Month
-
Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023
-
Exagen to Announce First Quarter 2023 Financial Results on May 15, 2023
-
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023
-
Exagen to Announce Fourth Quarter and Full Year Financial Results on March 20, 2023
-
Exagen Inc. to Participate in Upcoming March Conferences
-
Exagen Inc. to Participate in Upcoming March Conferences
-
Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
Exagen Inc. to Participate in the 2023 BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference
-
Exagen Inc (XGN) Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
-
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
-
Exagen Inc. Elects Tina S. Nova, Ph.D. as Executive Chair of the Board of Directors
-
Exagen Inc. Reports Third Quarter 2022 Results
-
Exagen Inc. Reports Third Quarter 2022 Results

